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Abstract: Elite athlete status is a partially heritable trait, as are many of the underpinning 
physiological, anthropometrical, and psychological traits that contribute to elite performance. In 
recent years, our understanding of the specific genetic variants that contribute to these traits has 
grown, such that there is considerable interest in attempting to utilise genetic information as a tool 
to predict future elite athlete status. In this review, we explore the extent of the genetic influence on 
the making of a sporting champion and we describe issues which, at present, hamper the utility of 
genetic testing in identifying future elite performers. We build on this by exploring what further 
knowledge is required to enhance this process, including a reflection on the potential learnings from 
the use of genetics as a disease prediction tool. Finally, we discuss ways in which genetic 
information may hold utility within elite sport in the future, including guiding nutritional and 
training recommendations, and assisting in the prevention of injury. Whilst genetic testing has the 
potential to assist in the identification of future talented performers, genetic tests should be 
combined with other tools to obtain an accurate identification of those athletes predisposed to 
succeed in sport. The use of total genotype scores, composed of a high number of performance-
enhancing polymorphisms, will likely be one of the best strategies in the utilisation of genetic 
information to identify talent in sport.  
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1. Introduction 
It is widely recognised that some individuals are naturally talented in specific physical traits that 
are, in turn, related to sports performance [1]. In some cases, talented individuals come from talented 
families, suggesting that genetics is partially responsible for the physical, physiological or 
anthropometric characteristics that are needed for attaining athletic success [2]. Indeed, elite athlete 
status is partially heritable, with twin studies suggesting that 30–80% of the variance in this trait is 
explained by heritable factors [3]. Recent advances in genetic technology have allowed for greater 
exploration of the genetic underpinnings of elite performance, leading to the identification of single 
nucleotide polymorphisms (SNPs) and other genetic variants with the potential to influence sports 
performance, either directly or indirectly. For example, a SNP in ACTN3, R577X (rs1815739), has been 
shown to modify the attainment of elite speed–power athlete status [4,5]. Here, a common C-to-T 
base substitution results in the transformation of an arginine base (R) to a premature stop codon (X). 
X allele homozygotes are deficient in the protein encoded for by ACTN3, α-actinin-3, which is 
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expressed exclusively in fast twitch muscle fibres. As a result, XX genotypes tend to have lower 
proportions of fast-twitch muscle fibres [6] and, because fast-twitch muscle fibres are an important 
component of speed–power performance, these genotypes might be underrepresented in elite speed–
power cohorts [7]. The first study on this topic was conducted by Yang and colleagues [7], who 
reported that the X allele was significantly less frequent in elite male and female sprint athletes than 
in non-athletic controls and elite endurance athletes. Whilst in Caucasian populations the frequency 
of the XX genotype is ~20%, in Yang and colleague’s [7] cohort of Caucasian power Olympians, the 
XX genotype was entirely absent. The finding of significantly lower frequencies of the X allele and 
XX genotypes in elite speed–power athletes has been replicated [8,9], although equivocal findings 
have also been reported elsewhere [10]. Consequently, despite generally being estimated to explain 
around 1–3% of the variance in speed–power phenotype [2,11,12], ACTN3 has subsequently been 
labelled a “gene for speed” [13–15]. ACTN3, however, is not the only gene associated with elite athlete 
status, with a recent review reporting that at least 155 genetic markers are potentially linked to elite 
athlete status, at least in some cohorts or ethnicities [16].  
Whilst many of the currently established SNPs associated with elite athlete status are associated 
with physiological traits such as aerobic capacity, muscle strength or speed, there is the potential that 
other SNPs may exert a less direct—but no less important—effect on the attainment of elite sports 
performance. For example, both height [17] and body mass index are highly heritable [18], and both 
likely contribute to the achievement of elite athlete status on a sport-by-sport basis. Furthermore, 
psychological traits are also genetically influenced, with a number of SNPs associated with anxiety 
[19]. Interestingly, it has been found that variants in genes coding for proteins potentially modulating 
activity of brain emotion centers, particularly in genes encoding elements of serotoninergic, 
catecholaminergic and hypothalamic–pituitary–adrenal systems might also influence the 
predisposition to elite sports performance [20]. As such, the genetic influence on sporting 
performance is broad, multi-factorial, and pervasive.  
Given the wide-ranging and potential influence of genetic variations on the attainment of elite 
athlete status, there is considerable interest in collecting genetic information to identify athletes with 
the potential to achieve elite status. Indeed, the number of companies that offer direct-to-consumer 
(DTC) genetic testing to predict sports performance/injury risk associated with sport has rocketed in 
recent years (Figure 1). Moreover, contemporary reports detail the use of genetic testing within the 
talent identification process in a number of countries and for a wide-range of sport enthusiasts [21]. 
One of the concerns with the use of such DTC genetic testing is that the information provided by the 
companies is based on a very limited genetic analysis, while the misuse of the research evidence to 
endorse the utility of this type of testing for early talent selection is common. The pace of growth in 
the number of companies that offer DTC genetic testing occurs partially due to the absence of 
worldwide agreements for a common regulation on this type of genetic testing. For these reasons, the 
general consensus amongst researchers is that these tests should not be used for talent identification 
[21], and the use of such tests in this way is ethically troubling [22]. Here, we discuss why current 
genetic tests cannot predict future sporting success, and explore the necessary advancements 
required to enable the utilisation of genetic information to accurately identify future talented 
performers. 
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Figure 1. Number of companies that offer direct-to-consumer (DTC) genetic testing marketed as being 
related to sport performance, exercise performance and sports injury risk. Data in 2019 has been 
obtained by using the search terms “genetic”, “test”, “exercise” and “sport” in two popular search 
engines (Google and Bing) replicating the procedures followed by Williams et al., in 2013 [23] and 
Webborn et al., in 2015 [21]. 
2. Why We Cannot Currently Use Genetic Information for Talent ID 
As previously mentioned, over 155 genetic markers have been tentatively linked with elite 
athlete status [16], although the association of most of these genetic variants to sports performance 
has a weak scientific background. The various suggestive genetic variants are typically—but not 
always—divergent, such that they predispose towards an increased chance of success in either 
power–strength or endurance sports/events, but not both. These divergent effects demonstrate that 
there is not a singular genetic profile that confers sporting success, but that the required genetic 
profiles are likely specific for characteristics of each sport. Whilst some of these markers, such as the 
aforementioned ACTN3 rs1815739 [5,7], and to a lesser extent angiotensin-converting enzyme (ACE) 
insertion (I)/deletion (D) polymorphism (rs1799752) [5,24], and peroxisome proliferator-activated 
receptor gamma coactivator 1-alpha (PPARGC1A or simply PGC1-1α) rs8192678 [25,26] have been 
replicated in some studies; others, such as transcription factor A, mitochondrial (TFAM) rs1937, have 
yet to be satisfactorily replicated [27]. Of the 155 genetic variants identified as linked to elite athlete 
status [16], 31 have been associated with elite athlete status in at least two studies, with 12 replicated 
in at least three [16]. Accordingly, at present, we know only a few of the genetic markers that likely 
associate with elite athlete status, making predictions of future sporting prowess based on such 
information not only difficult but also likely inaccurate. In addition, testing the utility and efficacy of 
genetic testing in the talent identification process should be conducted to ascertain whether the 
information provided by genetic testing—and not obtained through other traditional non-genetic 
tests such as physical testing—is of relevance to increase the specificity of overall talent selection [28].  
Another issue is that the currently available markers appear to offer poor specificity and 
sensitivity as talent identification tools. Returning to ACTN3 rs1815739, whilst the R allele is 
associated with elite athlete status in speed–power sports events [5], with the XX genotype potentially 
playing a negative role in performance in such types of events [7], it remains unclear how 
discriminatory this information might be. In Caucasians, for example, ~80% of individuals possess 
an R allele [7]. In some black African populations, this percentage can be as high as 99% [29]. In a 
study of elite US and Jamaican sprinters—the populations providing the fastest eight 100 m runners 
of all time—there was no significant difference in ACTN3 genotype frequencies between these 
athletes and their non-athletic peers, with 97% of non-athletes possessing at least one R allele [10]. 
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Therefore, whilst the R allele may be required for elite sprint performance, as the vast majority of the 
world’s population possess it, knowledge of an individual’s ACTN3 genotype is not particularly 
useful from a talent identification perspective. Furthermore, there are exceptions to the belief that an 
R allele is required for elite speed–power performance. In their study of elite sprinters, Papadimitriou 
and colleagues [12] reported that one male and one female 100 m sprinter, both of whom achieved 
the Olympic qualifying standard, did not possess an R allele. Additionally, Lucia and colleagues [30] 
reported the case of a long-jumper with a personal best of 8.26 cm, just 5 cm off the gold medal 
winning jump at the 2012 Olympic Games, who had the XX genotype. Such findings demonstrate 
that the lack of an ACTN3 R allele does not preclude attainment of elite status in speed–power events. 
Additionally, performance-enhancing polymorphisms may still have a low prevalence in elite athlete 
populations. For example, a SNP (rs7181866) in nuclear respiratory factor 2 (NRF2) gene has been 
associated with elite athlete status, with a significantly higher proportion of the AG genotype 
compared to the AA genotype found in elite endurance athletes when compared to controls [9]. 
However, only 12–14% of these elite athletes possessed the “ideal” AG genotype, illustrating that the 
vast majority of elite athletes did not have this specific performance-enhancing polymorphism, again 
potentially limiting its use as a discriminating screen. 
Such findings demonstrate the difficulties of a single gene approach for talent identification, 
highlighting that such an approach is no longer viable. In light of these findings, researchers have 
turned to Total Genotype Scores (TGS), whereby a number of elite athlete-associated SNPs are 
combined into a single polygenic score. Ruiz and colleagues [31,32] utilised this approach involving 
elite endurance and power athletes. For their study focusing on endurance athletes, they combined 
seven polymorphisms into a total score, finding that the mean score was higher in the athlete group 
than in the control (non-athletic) group [31]. This finding was replicated using a TGS comprised of 
six SNPs for power athlete status, with elite power athletes having a higher score than both endurance 
athletes and non-athletic controls [32]. Possession of the “perfect” polygenic profile (i.e., the elite 
athlete genotype of all SNPs) was rare, occurring in only 9.4% of the power athletes, and in no 
endurance athletes. In addition, there was considerable overlap between groups, such that a number 
of controls had better TGS than some elite power and endurance athletes [32]. Furthermore, whilst a 
TGS may help in discriminating between athlete and non-athlete, Santiago and colleagues [33] 
demonstrated that, in a group of rowers, it did not distinguish between different levels of 
performance (i.e., World vs National medallists). Earlier work [34,35] demonstrates that there is 
considerable similarity in polygenic scores within humans—athletes and non-athletes alike—when a 
low number of markers (in this case, 22 and 23) are used, such that, again, this approach would likely 
have limited real world specificity and sensitivity. Lastly, the configuration of TGS to differentiate 
between populations of athletes usually confers the same score to each SNP while the individual 
influence of each gene to the status of elite athlete is likely uneven, with some genetic variants 
exerting a greater influence than others. In order to improve the insights provided, a far greater 
number of performance-enhancing polymorphisms are likely required, whilst the relative weighing 
of the influence of each SNP may add further value in the development of increasingly accurate TGS. 
As such, further work should seek to identify additional SNPs associated with elite athlete status 
across a variety of sporting phenotypes, and replicate existing SNPs such that there is a pool of SNPs 
associated with elite athlete status that researchers have confidence in. The relative contribution of 
each SNP towards elite athlete status could then be determined via assessing the predictive ability of 
differently weighted algorithms, which can then be tested in hold-out cohorts for validation.  
As a summary of the above discussion, it seems clear that the provision of elite athlete status is 
a highly complex, polygenic trait, and that we know very few of the genetic variations that contribute 
to such a trait. As a result, it appears a fundamental requirement that, if genetic testing is to be utilised 
for talent identification purposes, a far greater number of polymorphisms associated with elite athlete 
status needs to be uncovered and then combined into a complex TGS model.  
3. What Further Knowledge Do We Require to Potentially Use Genetic Information for Talent 
Identification? 
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3.1. Genome-Wide Association Studies 
The evolution of Genome-Wide Association Study (GWAS) methodology potentially offers an 
opportunity to expand the number of genetic variants currently associated with elite athlete status, 
or to other traits associated with sporting success, such as the likelihood of suffering performance-
limiting injuries [36]. Whilst the majority of the SNPs currently associated with elite athlete status 
were elucidated via gene-association studies or candidate gene analysis—where a limited number of 
SNPs are hypothesised to have an effect on some particular trait associated with exercise 
performance, and that hypothesis is tested—GWAS are hypothesis-free. In a GWAS, a large number 
of SNPs are analysed for association with a specific trait. Given that there is no hypothesis to be tested, 
it provides a robust method to detect novel associations. However, due to the very low p-values 
required to reach genome-wide significance (p < 5 × 10−8), and the (often) very low effect sizes of any 
SNP, GWAS studies require very large subject numbers and might fail to identify some variations 
with a small effect. This is problematic when it comes to research on elite athletes, who are, by 
definition, rare. This problem was encountered in a GWAS carried out in multiple cohorts of elite 
endurance athletes by Rankinen and colleagues [37]. The authors utilised a cohort of elite Caucasian 
endurance runners (n = 315) and controls, along with a cohort of elite Japanese runners (n = 60) and 
controls, for the discovery phase of the GWAS. Following this discovery phase, in which no SNP met 
genome-wide significance, forty-two suggestive SNPs were taken through to a replication phase 
involving endurance athletes and controls from seven other countries, and from different ethnicities. 
Again, no genome-wide significant SNPs were found, although upon meta-analyses, a single SNP, 
rs558129 in polypeptide N-Acetylgalactosaminyltransferase 6 (GALNTL6) gene, was significant, with 
the T allele less frequent in athletes than in controls. As such, the authors summarised that there 
appeared to be no common SNP associated with elite endurance athlete status across this cohort, 
although they acknowledged their low sample size as a major limiting factor. This limitation is 
difficult to overcome and represents a significant roadblock in the search for genetic variants 
associated with elite performance. One potential method is to conduct a GWAS-approach analysis in 
a cohort of interest, and then attempt to replicate the suggestive findings (i.e., those of suggestive, 
but not genome-wide, statistical significance) of this analysis in additional, hold-out cohorts. Whilst 
novel, this approach has only been used in few sport genetics studies [38,39], despite its potential 
promise. A further potential roadblock is that there may be different associations between SNPs and 
elite performance across ethnicities, such that a SNP may be performance enhancing in Caucasians, 
but not in East Asians, for example, thereby requiring the development of ethnicity-specific SNP 
panels for the purpose of talent identification. 
3.2. Rare Variants 
A further avenue for exploration is that of rare gene variants that may predispose to elite 
performance. Generally, research focuses on common variants present in >1% of the population (i.e., 
polymorphisms) [2]. However, there are a few identified genetic variants which are very rare, and 
yet have the potential to positively affect performance. One such variant occurs at rs121917830 within 
the erythropoietin receptor (EPOR) gene. This variation is linked to a disease called erythrocystosis-
1, where affected people have increased red blood cell production, and hence greater oxygen carrying 
capacity [2]. This outcome is potentially advantageous for endurance sports, and in fact one elite 
athlete, the Finnish cross-country skiing champion Eero Mantyranta, is known to possess this variant 
[40]. Preliminary data suggest an additional example of a rare variant, this time affecting the 
lamin/AC (LMNA) gene—related to muscular dystrophy—that was found in Canadian sprint hurdler 
Priscilla Lopes-Schliep [41]. Finally, a rare variation in the myostatin gene (MSTN) has been reported, 
in which the carrier was described as “extraordinarily muscular” [42]. Such a variation would 
perhaps be advantageous in sports/events demanding high levels of strength and muscle mass. One 
issue with the exploration of rare performance-enhancing variants is that, given their very low 
frequency, they can be hard to identify. In addition, studies of rare variants would need very large 
samples of unrelated individuals to correctly identify the influence of the variant on athletic 
performance. Lastly, some variants might also predispose to disease states; a factor raising complex 
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moral and ethical questions. However, despite these potential issues, research continues towards 
their identification [41], not least because identification of individuals with disease-causing variants 
but presenting with a good health status could provide information relating to the underpinning 
mechanisms of these diseases and provide insight into remedial and resilience-building strategies 
[43].  
3.3. A Predictive Threshold 
An area of potential previous confusion is the number of performance-enhancing 
polymorphisms an individual may require before they are capable, from a genetic standpoint, of elite 
performance. Both Williams and Folland [34] and Hughes and colleagues [35] report that, in panels 
containing 23 (endurance) and 22 (strength–power) polymorphisms, the chances of one athlete 
possessing all was vanishingly small. As such, it seems unlikely that a single athlete possesses the 
“perfect” genetic profile, and it could be argued that having such a perfect profile is arguably 
unnecessary. Instead, athletes will likely possess a given number of performance-enhancing 
polymorphisms. Crucially, the polymorphisms possessed will differ between athletes, such that there 
might be only minimal overlap between individuals. In this way, once a large number of SNPs 
responsible for driving elite athlete status are uncovered—should such discovery ever occur—there 
will be the potential for the development of a threshold number, whereby possession of 
polymorphisms above this number would be associated with elite performance. Accordingly, there 
will not necessarily be a commonality in terms of the genetic variants present, although some 
crossover will certainly occur; instead, the main driving factor will be the total frequency of 
performance-driving variants. These SNPs will also likely differ between ethnicities, and so ethnicity-
specific thresholds and genetic panels will be required. The utilisation of a large number of SNPs 
reduces the reliance on individual SNPs that occur either at high frequencies across populations (such 
as the ACTN3 R allele), or those that, whilst linked to elite athlete status, are still present at relatively 
low frequencies in elite cohorts (for example the NRF2 G allele).  
3.4. Epigenetic Modifications 
In addition to genetic variations that might predispose, at least partially, to elite performance in 
a given sports, favourable epigenetic modifications that predispose to a natural talent trait (direct 
effect), and/or enhanced response to physical training and reduced risk of injury (indirect effect; 
(Figure 2)) would also likely be advantageous. In this context, epigenetic modifications—changes in 
genetic expression that are not due to variations in the underlying genetic code—may modify the 
attainment of elite athlete status [44] and represent another source of heritable variation that might 
help in sports talent identification [2]. These epigenetic changes are typically comprised of DNA 
methylation, histone modifications, and non-coding RNAs, particularly microRNAs (miRNAs) 
[44,45]. For example, miRNAs are involved in post-transcriptional control of messenger RNA 
(mRNA) and they include a highly complex network that regulates protein expression within the cell. 
Sequence and functional conservation of many human miRNAs with distantly related organisms 
suggests their crucial role in cellular progress [46]. Given their fundamental role in cell functioning, 
miRNAs have been shown to influence both skeletal muscle differentiation [47] and the magnitude 
of exercise-induced adaptations [48], which are important components of the journey towards elite 
athlete status. The use of epigenetic information might help to discover individuals with high chances 
of possessing characteristics associated with elite sport performance, but also to understand what 
and how epigenetic modifications can be modulated through appropriate training and dietary 
regimes to improve performance [2]. As of yet, whilst it appears that epigenetic changes may modify 
the response to exercise [44,45], it is not clear what overall effect they may have on the attainment of 
elite status. Additionally, such modifications have the potential to be passed down through 
generations [49], and thus might form part of the heritable aspect of elite athlete status, although the 
evidence that this actually occurs in humans is currently weak. Nevertheless, the ability to test for 
these changes, which are often tissue-specific, could assist in the identification of talented athletes; 
however, the quantification of epigenetic modifications can, in some cases, be challenging. Many 
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epigenetic modifications are often both tissue specific and transient [50]; as a result, quantification 
would require frequent tissue sampling, which in the case of muscle would be invasive and 
traumatic, and in the case of other tissue, such as the heart and brain, highly impractical [51]. 
However, early research suggests that salivary profiling of DNA methylation markers holds promise 
[52], making this approach potentially more attractive and practically realistic.  
 
Figure 2. Influence of genetics and epigenetics on traits associated with elite performance. To succeed 
in sport, an athlete must possess genetic and epigenetic variations that might predispose to a natural 
talent trait (direct effect), and/or to enhanced response to physical training, and/or to reduced risk of 
injury (indirect effect). 
3.5. Lessons from Disease Prediction 
One area where the use of genetics to make informed predictions of a future event has been well 
explored is that of disease risk. Whilst some diseases, such as cystic fibrosis, are monogenic, most 
diseases are complex and polygenic in nature [53]. Similar to elite athlete status, whilst many diseases 
have been shown to have a large genetic component, the disease-causing variants identified to date 
explain little of the variance between individuals; an issue referred to as the ‘missing heritability’ 
problem [54]. One suggested approach to overcome the problem of missing heritability is to lower 
the threshold for discovery of SNPs affecting the trait of interest. Due to the high number of 
comparisons carried out in a GWAS, statistical significance for discovery of new variants is set at p < 
5 × 10−8. However, the lowering of this threshold has been shown to lead to explanation of a greater 
proportion of heritability [55]. Recently, Khera and colleagues [56] utilised a TGS comprised of 
6,630,150 polymorphisms to create a risk score for coronary artery disease that had an area under the 
curve of 0.81, suggesting a strong predictive ability; many of these polymorphisms had miniscule 
effect sizes and weak significance, and yet combined to produce a powerful predictive tool. Such a 
method clearly holds promise for traits that have a large—but poorly elucidated—genetic component 
[57], such as elite athlete status. Indeed, returning to the recent GWAS on elite endurance status, 
whilst no SNP was discovered at the genome-wide significance level (p < 5 × 10−8), a number of SNPs 
had suggestive significance, and so may hold predictive ability as part of a TGS. As such, it appears 
that, in order to successfully predict future elite athlete status, models involving multiple genetic 
variants with low effect sizes are likely required, although this approach has recently been criticised 
from a disease-prediction viewpoint [58]. However, we return to the common issue of sample size; 
for discovery of relatively common genetic variants with small effect sizes, sample sizes in excess of 
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10,000 subjects are likely required [59]—a number considerably greater than that of all truly elite 
athletes within a specific performance trait on the planet.  
4. Even If We Could Test for Talent—Should We? 
There are serious and well-placed concerns about the use of genetic information, either alone or 
in combination with existing measures, for talent identification within sport [21]. It is generally 
considered that, within sporting contexts, genetic testing should not be carried out on athletes 
younger than 18 years of age [21]. If genetic testing for talent does become evidence-based, then there 
will be a requirement for the development of guidelines on its use, in part to protect vulnerable young 
children. For example, should sports clubs be able to demand players undergo genetic testing as part 
of their talent identification programmes? Who should have access to the genetic data? Will it be used 
in a discriminatory way? What if a player refuses to undergo a genetic test? What happens if testing 
uncovers a potential disease-causing variant? The latter point is potentially an important issue, as 
whilst it could lead to health-promoting medical interventions, it could also lead to unnecessary 
medical explorations, as well as increased worry, both on the part of the athlete tested and their 
relatives, who may also carry the disease-causing variant. Such outcomes are highly unpalatable, and 
likely represent an extreme example, but demonstrate the potential misuse of genetic information for 
talent identification.  
If and when genetic testing is used to predict future elite athlete status, there will be many false 
positives and false negatives (i.e., many individuals will be misattributed to future elite or non-elite 
status [60]). Whilst such error rates may be acceptable at a population level, they are obviously 
ethically troubling at an individual one—who has the right to tell a young athlete that they do not 
have the genetic potential to succeed in a given sport? Perhaps more importantly, what impact would 
receiving this information have on that individual’s future exercise behaviour, which, given the wide-
ranging health benefits of exercise [61], is an important consideration for lifelong health. For these 
reasons, some authors have suggested that emphasis in the use of genetic testing for talent 
identification in children needs to be focused on the wellbeing on the child in the present, not on the 
potential of future benefits that may never arrive [22].  
5. What Could We Potentially Use Genetic Testing for? 
It has previously been argued that, instead of using genetic information for talent identification 
in the traditional sense, this information could be used to match individuals to the type of training to 
which they are most suited, and from which they will elicit the greatest adaptations [62–64]. 
Additionally, genetic information could be utilised to identify those athletes with an increased risk 
of injury, allowing for the provision of pre-emptive strategies to reduce that risk. For example, Varley 
and colleagues [65] identified a number of polymorphisms associated with an increased stress 
fracture risk in a cohort of elite athletes; in this case, the high-risk athletes could undergo additional 
bone mineral density monitoring, along with targeted interventions, such as vitamin D and calcium 
supplementation.  
Whilst traditional research has focused on the physiological drivers of elite athlete status 
(reviewed in detail by Ahmetov and colleagues [16]), there is the potential to explore the genetic 
underpinnings of psychological factors, such as anxiety, stress resilience, and skill acquisition. This 
has not yet been explored in detail, although a SNP in catechol-O-methyltransferase (COMT) gene, 
rs4680, has been linked with competition performance in swimmers [66] and with personality traits 
in ultra-endurance athletes [67]. Catechol-o-methyltransferase plays a role in the regulation of 
dopamine within the prefrontal cortex [19]; variation in this SNP affects dopamine levels and thus 
information processing and memory [19]. Emerging research has also shown an association between 
a number of polymorphisms and the skill acquisition process [68]. Finally, a number of genetic 
variants have been linked to an increased susceptibility to concussion injuries [69]. As a result, whilst 
this information could be used to bias against those with the perceived “unfavourable” genotypes, it 
could also be used to personalize the training process, identifying those athletes who need greater 
attention in these areas. Furthermore, with regard to both injury and concussion, the information 
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could be used to better inform preventative methods, along with increasing the personalisation of 
recovery and return-to-play protocols, particularly given the evidence that genetic information might 
enhance adherence [70]. That said, similar to the use of genetic information as a talent identification 
tool, the research in this area is currently under-developed, and plagued with similar issues to those 
outlined in this manuscript. The early and initial studies exploring the use of genetic information to 
training programme design and management, whilst promising, require replication in different 
cohorts and larger samples to confirm their findings.  
6. Conclusions 
Although there is a well-established effect of genetics on the attainment of elite athlete status, 
based on the available evidence, it is clear that the current use of genetic tests for the prediction of 
future elite athlete status is ineffectual, a finding that echoes recent consensus statements [21,71]. 
Despite the increasing availability of commercial DTC genetic tests, the currently available data 
suggest the use of the information provided by these tests for talent identification or selection, 
especially in children, is unfounded. In order to be able to use genetic information within the talent 
identification process, a far greater number of performance-enhancing polymorphisms needs to be 
both discovered and replicated in subsequent studies. Future studies in elite athletes must contain 
detailed information on phenotypes associated with sporting performance, in conjunction with 
obtaining samples such as blood or muscle tissue that help identify the association between genetics 
and epigenetics. The combination of performance-enhancing polymorphisms into a TGS, especially 
if the evidence threshold is lowered, appears to offer a solution to the currently limited predictive 
capabilities of small numbers of genetic variants. As the evidence base grows, we believe it will be 
possible to determine a TGS threshold, above which an individual’s chance of achieving elite athlete 
status in a given sport or event is higher. However, we are also of the opinion that there will always 
be individuals with a score below this threshold who go on to achieve elite athlete status, and those 
with scores above the threshold who will not be elite athletes. Because elite athlete status is a 
manifestation of a number of variables, not just genotype, it seems unlikely that it will ever be 
possible to use genetic information to unequivocally identify a future elite athlete. At best, genetic 
information may represent a potentially useful adjunct to existing talent identification procedures, 
enhancing the process of selection, particularly as genetic information is not subject to some of the 
issues that commonly plague traditional talent identification processes, such as maturation and the 
relative age effect. Additionally, it has previously been argued that genetic information may be used 
in the future to identify those with the greatest potential to show favourable adaptations to training 
[62,64], as well as determine the optimal training type to elicit such adaptations [63]. Furthermore, 
there is the potential to utilise such information to reduce injury occurrence [72]. Again, and we must 
be clear; such information should not be used as a standalone, but as an adjunct to current talent 
identification processes, thereby allowing the training process to become more personalised, and 
enabling athletes to get ever closer to their maximum potential.  
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